Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
Conditions
Interventions
aceneuramic acid extended-release (Ace-ER)
Placebo
Locations
13
United States
University of California, Irvine
Irvine, California, United States
Washington University School of Medicine
St Louis, Missouri, United States
New York University School of Medicine
New York, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
UMHAT "Alexandrovska"
Sofia, Bulgaria
McMaster University
Hamilton, Ontario, Canada
Start Date
May 20, 2015
Primary Completion Date
June 9, 2017
Completion Date
June 9, 2017
Last Updated
June 27, 2019
NCT04671472
NCT00195637
NCT02731690
NCT01634750
NCT01517880
Lead Sponsor
Ultragenyx Pharmaceutical Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions